Keyword: Cadila Healthcare
The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.
Cadila's facility in St. Louis was cited by the FDA for observations after the company’s Moraiya plant was tagged by the agency last month.
India’s Cadila found a ray of sunshine in the fact that the FDA issued 14 observations during an inspection of its formulation plant in Moraiya.
A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.
Cadila's Liva subsidiary was hit with a Form 483 by the FDA following an inspection of its plant in Vadodara, India.
Indian drugmaker Cadila Healthcare said a recent FDA inspection of its facility at Changodar, Ahmedabad, resulted in no observations.
The list of drugmakers reportedly eying Bayer’s up-for-sale dermatology unit is growing even longer.
Indian drugmaker Cadila Healthcare said it received an Establishment Inspection Report (EIR) from the FDA for its facility in Ahmedabad.
The manufacturing issues continue to mount for India’s Cadila Healthcare. The drugmaker, which last year was hit with an FDA warning letter for two of its Indian plants, is now recalling several hundred thousand bottles of an antidepressant made at one of those plants.